Jianxin Chen

Dr. Jianxin Chen


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Theranostics
Verified
Journal Article
Open access
GXGangqin Xi
Gangqin Xi
WGWenhui Guo
Wenhui Guo
DKDeyong Kang
Deyong Kang
JMJianli Ma
Jianli Ma
FFFangmeng Fu
Fangmeng Fu
JCJianxin Chen
Jianxin Chen
The notion of personalized medicine demands proper prognostic biomarkers to guide the optimal therapy for an invasive breast cancer patient. However, various risk prediction models based on conventional clinicopathological factors and emergent molecular assays have been frequently limited by either a low strength of prognosis or restricted applicability to specific types of patients. Therefore, there is a critical need to develop a strong and general prognosticator.

24 May 2010 in Applied Physics Letters
Verified
Journal Article
Open access
PDF file
SZShuangmu Zhuo
Shuangmu Zhuo
JCJianxin Chen
Jianxin Chen
GWGuizhu Wu
Guizhu Wu
SXshusen xie
shusen xie
LZLiqin Zheng
Liqin Zheng
XZXiaoqin Zhu
Xiaoqin Zhu
Collagen alteration is critical for epithelial tumor initiation and progression. Quantitatively linking collagen alteration and epithelial tumor progression is essential for developing an optical endoscopy to evaluate epithelial tumor progression. In this work, we established a quantitative link between collagen alteration and epithelial tumor progression using second harmonic generation (SHG) microscopy. It was found that SHG microscopy can provide quantitative features to effectively evaluate epithelial tumor progression, and to locate tumor and determine the margin of tumor regions. These results suggest that SHG microscopy has the potential in offering a noninvasive in vivo imaging tool to quantify epithelial tumor progression.

22 June 2009 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
GCGuannan Chen
Guannan Chen
JCJianxin Chen
Jianxin Chen
SZS. Zhuo
S. Zhuo
SXS. Xiong
S. Xiong
Haishan ZengHaishan Zeng
Haishan Zeng
SXS. Xie
S. Xie

1 April 2011 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
JCJianxin Chen
Jianxin Chen
SZShuangmu Zhuo
Shuangmu Zhuo
GCGang Chen
Gang Chen
JYJun Yan
Jun Yan
HYHongquan Yang
Hongquan Yang
SXShusen Xie
Shusen Xie

14 September 2024 in Light: Science & Applications
Verified
Journal Article
Open access
PDF file
SWShu Wang
Shu Wang
JPJunlin Pan
Junlin Pan
XZXiao Zhang
Xiao Zhang
YLYueying Li
Yueying Li
WLWenxi Liu
Wenxi Liu
JCJianxin Chen
Jianxin Chen
Diagnostic pathology, historically dependent on visual scrutiny by experts, is essential for disease detection. Advances in digital pathology and developments in computer vision technology have led to the application of artificial intelligence (AI) in this field. Despite these advancements, the variability in pathologists’ subjective interpretations of diagnostic criteria can lead to inconsistent outcomes. To meet the need for precision in cancer therapies, there is an increasing demand for accurate pathological diagnoses. Consequently, traditional diagnostic pathology is evolving towards “next-generation diagnostic pathology”, prioritizing on the development of a multi-dimensional, intelligent diagnostic approach. Using nonlinear optical effects arising from the interaction of light with biological tissues, multiphoton microscopy (MPM) enables high-resolution label-free imaging of multiple intrinsic components across various human pathological tissues. AI-empowered MPM further improves the accuracy and efficiency of diagnosis, holding promise for providing auxiliary pathology diagnostic methods based on multiphoton diagnostic criteria. In this review, we systematically outline the applications of MPM in pathological diagnosis across various human diseases, and summarize common multiphoton diagnostic features. Moreover, we examine the significant role of AI in enhancing multiphoton pathological diagnosis, including aspects such as image preprocessing, refined differential diagnosis, and the prognostication of outcomes. We also discuss the challenges and perspectives faced by the integration of MPM and AI, encompassing equipment, datasets, analytical models, and integration into the existing clinical pathways. Finally, the review explores the synergy between AI and label-free MPM to forge novel diagnostic frameworks, aiming to accelerate the adoption and implementation of intelligent multiphoton pathology systems in clinical settings.

18 November 2021 in BMC Medicine
Verified
Journal Article
Open access
PDF file
GXGangqin Xi
Gangqin Xi
LQLida Qiu
Lida Qiu
SXShuoyu Xu
Shuoyu Xu
WGWenhui Guo
Wenhui Guo
FFFangmeng Fu
Fangmeng Fu
JCJianxin Chen
Jianxin Chen
Background: Collagen fibers play an important role in tumor initiation, progression, and invasion. Our previous research has already shown that large-scale tumor-associated collagen signatures (TACS) are powerful prognostic biomarkers independent of clinicopathological factors in invasive breast cancer. However, they are observed on a macroscale and are more suitable for identifying high-risk patients. It is necessary to investigate the effect of the corresponding microscopic features of TACS so as to more accurately and comprehensively predict the prognosis of breast cancer patients.Methods: In this retrospective and multicenter study, we included 942 invasive breast cancer patients in both a training cohort (n= 355) and an internal validation cohort (n= 334) from one clinical center and in an external validation cohort (n= 253) from a different clinical center. TACS corresponding microscopic features (TCMFs) were firstly extracted from multiphoton images for each patient, and then least absolute shrinkage and selection operator (LASSO) regression was applied to select the most robust features to build a TCMF-score. Finally, the Cox proportional hazard regression analysis was used to evaluate the association of TCMF-score with disease-free survival (DFS).Results: TCMF-score is significantly associated with DFS in univariate Cox proportional hazard regression analysis. After adjusting for clinical variables by multivariate Cox regression analysis, the TCMF-score remains an independent prognostic indicator. Remarkably, the TCMF model performs better than the clinical (CLI) model in the three cohorts and is particularly outstanding in the ER-positive and lower-risk subgroups. By contrast, the TACS model is more suitable for the ER-negative and higher-risk subgroups. When the TACS and TCMF are combined, they could complement each other and perform well in all patients. As expected, the full model (CLI+TCMF+TACS) achieves the best performance (AUC0.905, [0.873–0.938]; 0.896, [0.860–0.931]; 0.882, [0.840–0.925] in the three cohorts).Conclusion: These results demonstrate that the TCMF-score is an independent prognostic factor for breast cancer, and the increased prognostic performance (TCMF+TACS-score) may help us develop more appropriate treatment protocols.